UBS Group
CLDX icon

UBS Group’s Celldex Therapeutics CLDX Stock Holding History

UBS Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-213
Closed -$89K – 8517
2015
Q1 		$89K Buy
213
+146
+218% +$52.2K ﹤0.01% 5512
2014
Q4 		$18K Buy
+67
New +$16.7K ﹤0.01% 7786

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's CLDX Position: Q2 2026 in Review

UBS Group increased its Celldex Therapeutics (CLDX) stake by 62% in Q2 2026, buying an estimated $5.98M and bringing the position to 481,997 shares worth $17.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2801.

UBS Group first reported a position in CLDX in Q4 2014 and has held it in 47 quarters since. The position peaked at $26.6M in Q1 2025. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • UBS Group held 481,997 shares of Celldex Therapeutics worth $17.9M as of Q2 2026.
  • UBS Group bought 185,027 Celldex Therapeutics shares in Q2 2026, an estimated $5.98M.
  • Celldex Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2801 holding.
  • UBS Group first reported a position in Celldex Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Celldex Therapeutics position peaked at $26.6M in Q1 2025.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.